Published in Int J Gynecol Cancer on July 21, 2007
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol (2010) 1.06
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surg Today (2011) 0.90
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs (2009) 0.90
Targeted therapies in epithelial ovarian cancer. J Oncol (2010) 0.89
Antivascular therapy for epithelial ovarian cancer. J Oncol (2009) 0.80
Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. Oncol Lett (2016) 0.80
Targeted therapies in epithelial ovarian cancer. Cancers (Basel) (2010) 0.77
Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. Eur J Gynaecol Oncol (2013) 0.75
Neurotoxicity associated with cancer therapy. J Adv Pract Oncol (2012) 0.75
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med (1999) 7.56
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2000) 4.48
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
PTEN/MMAC1 mutations in endometrial cancers. Cancer Res (1997) 2.89
Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene (2007) 2.83
Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer (2006) 2.67
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology (2008) 2.33
Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst (1997) 2.30
Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. Arch Ophthalmol (2001) 2.30
Genetic instability of microsatellites in endometrial carcinoma. Cancer Res (1993) 2.20
Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol (2001) 2.20
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol (1995) 2.17
Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res (1986) 2.01
Cost-effectiveness of treatment of early stage endometrial cancer. Gynecol Oncol (1999) 1.99
Calpactins: two distinct Ca++-regulated phospholipid- and actin-binding proteins isolated from lung and placenta. J Cell Biol (1987) 1.81
Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet (1994) 1.81
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res (2000) 1.81
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol (1999) 1.66
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet (1999) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol (1996) 1.59
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol (1990) 1.59
PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res (1998) 1.58
Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res (2001) 1.56
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology (2009) 1.52
Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol (2001) 1.48
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol (1995) 1.47
Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery. Int J Radiat Oncol Biol Phys (1999) 1.46
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res (1998) 1.46
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ (1996) 1.45
A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol (1993) 1.44
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ (1994) 1.42
The role of partial sigmoid colectomy for debulking epithelial ovarian carcinoma. Gynecol Oncol (1991) 1.42
Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol (2001) 1.41
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst (1994) 1.39
Does early treatment with high-dose methylprednisolone alter the course of hepatic regimen-related toxicity? Bone Marrow Transplant (2000) 1.39
Primary appendiceal cancer: gynecologic manifestations and treatment options. Gynecol Oncol (2006) 1.38
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer (2008) 1.38
Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun (1998) 1.36
Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology (2010) 1.35
Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res (1995) 1.35
Cell cycle control of BRCA2. Cancer Res (1996) 1.32
Alterations in the morphology of lamina cribrosa pores in glaucomatous eyes. Br J Ophthalmol (2004) 1.31
Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys (1998) 1.29
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair. Nat Genet (1996) 1.28
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol (1995) 1.27
Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog (1996) 1.27
Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol (1997) 1.26
Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res (1993) 1.26
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology (2010) 1.26
Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler (2006) 1.25
Increased diffusivity in acute multiple sclerosis lesions predicts risk of black hole. Neurology (2010) 1.24
Leachability of elements from sub-bituminous coal fly ash from India. Environ Int (2002) 1.23
Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer (2006) 1.23
A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol (1996) 1.22
Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J Intern Med (2012) 1.20
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys (2001) 1.19
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer (2009) 1.19
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol (1993) 1.16
Gestational trophoblastic disease metastatic to the central nervous system. Gynecol Oncol (1995) 1.15
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst (1992) 1.13
Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res (1993) 1.13
The homozygous complete hydatidiform mole: a unique resource for genome studies. Genomics (1997) 1.13
A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res (1993) 1.12
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem (1992) 1.12
Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res (1992) 1.11
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther (2001) 1.10
Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther (2005) 1.10
Relationship between race and interval to treatment in endometrial cancer. Obstet Gynecol (1995) 1.08
Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol (1996) 1.08
Clinical significance of microsatellite instability in endometrial carcinoma. Cancer (2000) 1.07
Pelvic exenteration in gynecologic oncology: a single institution study over 20 years. Gynecol Oncol (2011) 1.07
Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol (1999) 1.06
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol (2001) 1.06
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med (1996) 1.05
Outcome of the current management of splenic injuries. J Trauma (2001) 1.04
Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer (1997) 1.04
Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer (1993) 1.04
5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol (1994) 1.03
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (1996) 1.03
Factors affecting long-term outcome of irradiation in carcinoma of the vagina. Int J Radiat Oncol Biol Phys (1999) 1.02
Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol (1990) 1.02
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer (2001) 1.02
Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer (1994) 1.02
Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res (1999) 1.02
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol (2000) 1.01
Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma. Cancer Genet Cytogenet (2000) 1.01
Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. Gynecol Oncol (1999) 1.01
Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res (1996) 1.01
Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int J Oncol (1999) 1.01
Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther (2004) 1.00